Advanced Search

    column
    Lung Cancer Immunotherapy 2.0: Total War
    ZHONG Wen-zhao, ZHANG Chao, WU Yi-long
    2017, 17(1): 1-4. DOI: 10.12019/j.issn.1671-5144.2017.01.001
    Abstract FullText HTML PDF
    Clinical Advances and Prospect of Lung Cancer Research in 2016
    YANG Jin-ji, WU Yi-long
    2017, 17(1): 5-8. DOI: 10.12019/j.issn.1671-5144.2017.01.002
    Abstract FullText HTML PDF
    An Incredible Pace Is Coming in the Future: 2016 Research Advances of Translational Medicine in Breast Cancer
    LIAO Ning
    2017, 17(1): 9-12. DOI: 10.12019/j.issn.1671-5144.2017.01.003
    Abstract FullText HTML PDF
    Hot Topics in 2016 Hematologic Tumor Immunotherapy
    CHEN Xiao-mei, DU Xing
    2017, 17(1): 13-16. DOI: 10.12019/j.issn.1671-5144.2017.01.004
    Abstract FullText HTML PDF
    2016 Research Advances in Lymphoma Treatment
    JIANG Xin-miao, LI Wen-yu
    2017, 17(1): 17-19. DOI: 10.12019/j.issn.1671-5144.2017.01.005
    Abstract FullText HTML PDF
    2016 Clinical Research Advances in Gastrointestinal Cancer
    MA Dong
    2017, 17(1): 20-22. DOI: 10.12019/j.issn.1671-5144.2017.01.006
    Abstract FullText HTML PDF
    2016 Clinical Advances in Head and Neck Neoplasms
    ZHENG Deng-yun, YANG Li-hui, GUAN Ji-lin
    2017, 17(1): 23-24. DOI: 10.12019/j.issn.1671-5144.2017.01.007
    Abstract FullText HTML PDF
    Advances in Diagnosis and Treatment of Pediatric Hematology and Oncology Diseases
    LIN Yu-deng, ZONG Sa
    2017, 17(1): 25-28. DOI: 10.12019/j.issn.1671-5144.2017.01.008
    Abstract FullText HTML PDF
    Research Advances of Hepatocellular Carcinoma with Transarterial Therapy in 2016
    GOU Qing, CHEN Xiao-ming
    2017, 17(1): 29-33. DOI: 10.12019/j.issn.1671-5144.2017.01.009
    Abstract FullText HTML PDF
    Pembrolizumab Versus Chemotherapy for PD-L1 Positive Non-Small Cell Lung Cancer
    ZHUANG Jin-qi, LU Shun, ZHANG Ming-feng
    2017, 17(1): 34-36. DOI: 10.12019/j.issn.1671-5144.2017.01.010
    Abstract FullText HTML PDF
    T-Cell Transfer Immunological Therapy Targeting Mutant KRAS in Cancer
    LIU Xiao-qing, FAN Jie, HUANG Shu-mei
    2017, 17(1): 37-41. DOI: 10.12019/j.issn.1671-5144.2017.01.011
    Abstract FullText HTML PDF
    The Effect of Pembrolizumab and Standard Chemotherapy for Advanced, Non-Squamous Non-Small Cell Lung Cancer
    FAN Yun, ZHANG Jia-tao
    2017, 17(1): 42-45. DOI: 10.12019/j.issn.1671-5144.2017.01.012
    Abstract FullText HTML PDF
    EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer
    HU Yi, LIU Si-yang
    2017, 17(1): 46-49. DOI: 10.12019/j.issn.1671-5144.2017.01.013
    Abstract FullText HTML PDF
    Compare the Curative Effect of Pembrolizumab and Docetaxel for Previously Treated PD-L1-Positive Advanced Non-Small Cell Lung Cancer
    SONG Yong, ZHANG Chao
    2017, 17(1): 50-54. DOI: 10.12019/j.issn.1671-5144.2017.01.014
    Abstract FullText HTML PDF
    The Predictive Value of Plasma Soluble OX40 Ligand on the Major Adverse Cardiovascular Events after Percutaneous Coronary Intervention
    GUO Jin-jun, WANG Yu-ting, YU Hong-wei
    2017, 17(1): 55-58. DOI: 10.12019/j.issn.1671-5144.2017.01.015
    Abstract FullText HTML PDF
    Evidence-Based Treatment for Early-Stage Breast Cancer Patients after Breast-Conserving Surgery Treated with External Beam Accelerated Partial-Breast Irradiation
    ZHENG Jian-qing, HUANG Bi-fen, LIU Jing-jing, CHEN Ming-fen, SU Jing-jing, CAI Qun-rong, BAI Zhi-gang
    2017, 17(1): 59-64. DOI: 10.12019/j.issn.1671-5144.2017.01.016
    Abstract FullText HTML PDF